Lineage Cell Therapeutics, Inc. Equity Method Investment, Ownership Percentage
Lineage Cell Therapeutics, Inc. (LCTX) had Equity Method Investment, Ownership Percentage of 20.00% as of 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Notes › Investments › Equity Method Investments and Joint Ventures
us-gaap:EquityMethodInvestmentOwnershipPercentage · last filed 2020-03-12
- 2018-12-31: Equity Method Investment, Ownership Percentage 20.00%.
- 2017-12-31: Equity Method Investment, Ownership Percentage 20.00%.
- 2017-07-10: Equity Method Investment, Ownership Percentage 99.80%.
- 2016-06-30: Equity Method Investment, Ownership Percentage 57.10%.
| Period end | Equity Method Investment, Ownership Percentage |
|---|---|
| 2018-12-31 | 20.00% 10-K · filed 2019-03-14 |
| 2017-12-31 | 20.00% 10-K · filed 2018-03-15 |
| 2017-07-10 | 99.80% 10-K · filed 2020-03-12 |
| 2016-06-30 | 57.10% 10-Q · filed 2016-08-09 |
| 2015-12-31 | 20.00% 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |